Diabetes Mellitus, Type 2
"Diabetes Mellitus, Type 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
MeSH Number(s)
C18.452.394.750.149
C19.246.300
Concept/Terms
Diabetes Mellitus, Type 2- Diabetes Mellitus, Type 2
- Diabetes Mellitus, Ketosis-Resistant
- Diabetes Mellitus, Ketosis Resistant
- Ketosis-Resistant Diabetes Mellitus
- Diabetes Mellitus, Maturity-Onset
- Diabetes Mellitus, Maturity Onset
- Diabetes Mellitus, Non Insulin Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Non-Insulin-Dependent Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Diabetes Mellitus, Slow-Onset
- Diabetes Mellitus, Slow Onset
- Slow-Onset Diabetes Mellitus
- Diabetes Mellitus, Stable
- Stable Diabetes Mellitus
- Diabetes Mellitus, Type II
- Maturity-Onset Diabetes Mellitus
- Maturity Onset Diabetes Mellitus
- MODY
- NIDDM
- Diabetes Mellitus, Adult-Onset
- Adult-Onset Diabetes Mellitus
- Diabetes Mellitus, Adult Onset
- Diabetes Mellitus, Noninsulin Dependent
Below are MeSH descriptors whose meaning is more general than "Diabetes Mellitus, Type 2".
Below are MeSH descriptors whose meaning is more specific than "Diabetes Mellitus, Type 2".
This graph shows the total number of publications written about "Diabetes Mellitus, Type 2" by people in Harvard Catalyst Profiles by year, and whether "Diabetes Mellitus, Type 2" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 18 | 8 | 26 |
1995 | 22 | 8 | 30 |
1996 | 21 | 11 | 32 |
1997 | 23 | 6 | 29 |
1998 | 34 | 14 | 48 |
1999 | 34 | 11 | 45 |
2000 | 35 | 11 | 46 |
2001 | 41 | 11 | 52 |
2002 | 56 | 25 | 81 |
2003 | 78 | 27 | 105 |
2004 | 87 | 29 | 116 |
2005 | 91 | 29 | 120 |
2006 | 122 | 20 | 142 |
2007 | 146 | 37 | 183 |
2008 | 148 | 38 | 186 |
2009 | 144 | 32 | 176 |
2010 | 177 | 41 | 218 |
2011 | 178 | 49 | 227 |
2012 | 246 | 52 | 298 |
2013 | 227 | 40 | 267 |
2014 | 227 | 55 | 282 |
2015 | 233 | 36 | 269 |
2016 | 251 | 62 | 313 |
2017 | 251 | 52 | 303 |
2018 | 281 | 51 | 332 |
2019 | 328 | 48 | 376 |
2020 | 335 | 46 | 381 |
2021 | 355 | 38 | 393 |
2022 | 436 | 7 | 443 |
2023 | 414 | 4 | 418 |
2024 | 58 | 0 | 58 |
Below are the most recent publications written about "Diabetes Mellitus, Type 2" by people in Profiles.
-
The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2024 Apr 01; 47(4):638-645.
-
Lifetime Duration of Breastfeeding and Cardiovascular Risk in Women With Type 2 Diabetes or a History of Gestational Diabetes: Findings From Two Large Prospective Cohorts. Diabetes Care. 2024 Apr 01; 47(4):720-728.
-
Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2024 Apr 01; 47(4):610-619.
-
Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study. Diabetes Care. 2024 Apr 01; 47(4):712-719.
-
Effects of Diabetes Mellitus on Corneal Immune Cell Activation and the Development of Keratopathy. Cells. 2024 Mar 18; 13(6).
-
Telomere length as biomarker of nutritional therapy for prevention of type 2 diabetes mellitus development in patients with coronary heart disease: CORDIOPREV randomised controlled trial. Cardiovasc Diabetol. 2024 Mar 16; 23(1):98.
-
Polycystic Ovary Syndrome Physiologic Pathways Implicated Through Clustering of Genetic Loci. J Clin Endocrinol Metab. 2024 Mar 15; 109(4):968-977.
-
The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout. Nat Rev Rheumatol. 2024 Apr; 20(4):216-231.
-
Postprandial glucose variability and clusters of sex hormones, liver enzymes, and cardiometabolic factors in a South African cohort of African ancestry. BMJ Open Diabetes Res Care. 2024 Mar 07; 12(2).
-
Delivery Device Patents on GLP-1 Receptor Agonists. JAMA. 2024 03 05; 331(9):794-796.